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Abstract
Due to their similarity to tobacco cigarettes, electronic cigarettes (e-cigarettes) could play an important role in
tobacco harm reduction. However, the public health community remains divided concerning the appropriateness
of endorsing a device whose safety and efficacy for smoking cessation remain unclear. We identified the major
ethical considerations surrounding the use of e-cigarettes for tobacco harm reduction, including product safety,
efficacy for smoking cessation and reduction, use among non-smokers, use among youth, marketing and
advertisement, use in public places, renormalization of a smoking culture, and market ownership. Overall, the safety
profile of e-cigarettes is unlikely to warrant serious public health concerns, particularly given the known adverse
health effects associated with tobacco cigarettes. As a result, it is unlikely that the population-level harms resulting
from e-cigarette uptake among non-smokers would overshadow the public health gains obtained from tobacco
harm reduction among current smokers. While the existence of a gateway effect for youth remains uncertain,
e-cigarette use in this population should be discouraged. Similarly, marketing and advertisement should remain
aligned with the degree of known product risk and should be targeted to current smokers. Overall, the available
evidence supports the cautionary implementation of harm reduction interventions aimed at promoting e-cigarettes
as attractive and competitive alternatives to cigarette smoking, while taking measures to protect vulnerable groups
and individuals.
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Background
Electronic cigarettes (e-cigarettes) have polarized the
public health community unlike any previous alternative
to smoking. Although their efficacy as smoking cessation
aids remains unclear [1], anecdotal evidence suggests
that many people have successfully quit smoking with
the use of e-cigarettes. Due to their similarity in form
and function to tobacco cigarettes, e-cigarettes could
play an important role in tobacco harm reduction. How-
ever, intense divisiveness has resulted from the absence
of conclusive evidence demonstrating product safety for
individual and public health. Several ethical issues have
been identified pertaining to their use both as recre-
ational products and harm reduction devices, including
their potential appeal to non-smokers, their potential to
act as a gateway to cigarette smoking, and their potential
to renormalize a public smoking culture. To this end, we
examined the ethical issues surrounding the availability
and use of e-cigarettes for tobacco harm reduction, with
the objective of understanding their potential contribu-
tions to public health. Specifically, our framework draws
upon tensions between utilitarianism and liberalism in
public health ethics [2], the former aiming to produce
the largest public health gains through the greatest re-
duction in the burden of disease, and the latter holding
paramount individuals' right to self-determination in
health.
The burden of smoking-attributable disease
Cigarette smoking remains the leading cause of prevent-
able mortality worldwide, contributing to the death of
approximately 480,000 Americans annually [3]. Smoking
also produces substantial morbidity costs: estimates
show that 6.9 million Americans reported major
smoking-related morbidity in 2009, constituting 10.9
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million lifetime cases of smoking-attributable disease [4].
Cessation efforts have largely failed to address the wealth
of behavioral and social components to cigarette addic-
tion. The majority of the lifestyle benefits conferred by
cigarette smoking, including alertness, focus, stress re-
duction, and social opportunities [5, 6], are not compar-
ably paralleled with existing smoking cessation therapies.
In addition, among the strongest habit-forming proper-
ties of tobacco cigarettes are the behavioral cues associ-
ated with their use, including regular hand-to-mouth
action and the production of smoke [7, 8]. Conse-
quently, there is an urgent need for novel cessation
therapies that target both the physiological and be-
havioral components of cigarette smoking. A device
that retains the feel and function of cigarettes and re-
duces their associated health costs could lead to sub-
stantial public health benefits. Given their striking
similarity to tobacco cigarettes and their high degree
of acceptability among smokers [9–11], e-cigarettes
constitute the closest approximation to such a harm
reduction device to date.
The role of tobacco harm reduction in public health
Harm reduction policies attempt to diminish the dam-
aging effects of a particular behavior without aiming to
eliminate the behavior itself. Common applications in-
clude the provision of needle exchanges and safe injec-
tion kits to injection drug users, and the use of
methadone to treat opiate addiction. Despite continued
resistance to harm reduction interventions, there is
strong evidence demonstrating their successes in public
health, most notably in reducing the incidence of HIV
and Hepatitis C infection [12–14]. Critics may argue that
tobacco harm reduction, as it applies to e-cigarettes, re-
mains distinct from harm reduction for other forms of
drug addiction. While there is no definitive evidence that
either e-cigarettes or needle exchanges promote sub-
stance initiation among non-users, critics have expressed
concerns about the possibility of a gateway effect of e-
cigarettes towards conventional cigarettes [15]. In
addition, unlike e-cigarettes, needle exchanges are not
backed by powerful political lobbyists or for-profit com-
panies [15]. Lastly, injection drug use is comparably in-
visible relative to the conspicuousness of using an e-
cigarette in public [15]. While these important distinc-
tions highlight the need for closer examination, they do
not inherently exclude the harm reduction potential of
e-cigarettes.
The burden of smoking-related illness suggests that
novel public health interventions designed to reduce the
harms associated with cigarette smoking are needed. Vir-
tually all interventions to date have focused on eliminating
nicotine use, as standard nicotine replacement therapies
are indicated for use up to 12 weeks [16]. These successes
have been limited, with just over 15 % of smokers moti-
vated to quit achieving prolonged abstinence at 12 months
with the aid of a smoking cessation therapy [17]. Despite
the fact that an elimination-centered approach is incon-
gruous with the understanding that harm reduction strat-
egies are more practical and feasible than enforcing
population-wide abstinence [18], anti-tobacco activists
have expressed concern that harm reduction might over-
shadow cessation messages, effectively resulting in a re-
duction in the number of successful quitters [19].
Tobacco harm reduction continues to be met with
skepticism by public health advocates [20] whose distrust
of safer smoking products dates back to a misguided
endorsement of “light” cigarettes in the 1950’s and 60’s
[18, 21]. More recently, critics denounced the use of low-
nitrosamine smokeless tobacco products, commonly
known as “snus,” for tobacco harm reduction despite evi-
dence that the increased use of snus among Swedish men
was accompanied by a reduction in the prevalence of
cigarette smoking and tobacco-related disease [22, 23].
Arguments against the use of smokeless tobacco for harm
reduction are similarly used against e-cigarettes, including
the continued promotion of an addictive substance, uncer-
tain long-term safety concerns, the possibility of a gateway
effect to conventional tobacco products, and concerns
about questionable terms of engagement with the tobacco
industry [24]. An important distinction between e-cigarettes
and smokeless tobacco to be considered among public
health critics is the former’s inherent likeness to conven-
tional cigarettes, which arguably increases their appeal as
an alternative to knowingly harmful combustible products.
However, this distinction has not prevented significant
controversy and debate in the United Kingdom, stemming
from polarized opinions concerning the strength of the
evidence regarding e-cigarettes’ potential for harm [25].
The principal quandaries in framing e-cigarettes as a
tool for harm reduction occur first in determining
whether it is morally objectionable to promote a product
whose long-term health effects remain unknown; second,
in establishing whether mitigating a harm that already ex-
ists is morally superior to preventing a same or similar
harm from materializing [26]. What is the government’s
role in regulating and potentially incentivizing these prod-
ucts? Should physicians encourage tobacco harm reduc-
tion by advocating for the use of e-cigarettes? As they are
neither tobacco products nor approved cessation devices,
e-cigarettes constitute a novel product whose harm reduc-
tion potential stands to be weighed against the ethical im-
plications surrounding their availability and use.
Review
E-cigarette safety
E-cigarettes typically contain a solution of propylene gly-
col or glycerin, with or without nicotine, that is
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vaporized upon inhalation by the user [27]. Unlike to-
bacco cigarettes, e-cigarettes are free of combustion
[28], the mechanism through which toxicants contained
in burned tobacco are inhaled and absorbed by the user
[3]. To date, biochemical studies of e-cigarettes have
failed to raise any serious health concerns [3, 20]. The
most frequently reported adverse events associated with
their use have included nausea, throat and mouth irrita-
tion, headache, and dry cough, all of which were found
to resolve over time [3, 29]. Although e-cigarettes are
believed to have similar toxicity as existing nicotine re-
placement therapies [20], the generalizability of these
findings remains unclear given the absence of standard-
ized manufacturing practices and the proprietary nature
of industry studies. The product’s novelty also entails
that there is insufficient data to judge the long-term ef-
fects of regular inhalation of propylene glycol or gly-
cerin. However, studies of artificial smoke generators
concluded that exposure to propylene glycol mist can
cause ocular and upper airway irritation [30], which
could potentially be of concern among users with
chronic lung disease, including asthma, emphysema, or
bronchitis [31].
Safety evaluations will require quantifying the degree
of risk warranted in the face of incomplete evidence with
which to inform decision-making. In turn, promoting
autonomy, or the right to make individual decisions with
regards to one’s life choices, requires the provision of in-
formation concerning the risks and benefits associated
with a given behaviour and with voluntary choice [32].
This rights-based position is compelling given that the
majority of e-cigarette users are current smokers attempt-
ing to quit or reduce their number of cigarettes smoked
[33]. While autonomy may be compromised through the
influence of nicotine addiction, the consequences may be
less pronounced where this choice consists of selecting
between alternative sources of nicotine (of potential equal
or similar satisfaction), rather than choosing between in-
dulgence and abstinence. However, were the demograph-
ics of e-cigarette users to change, for instance through an
increased number of non-smokers or youth taking up e-
cigarettes, from a utilitarian perspective, the autonomy ar-
gument may become less convincing in weighing individ-
ual harm against public good.
Efficacy for smoking cessation and reduction
The best evidence concerning the efficacy of e-cigarettes
for smoking cessation and reduction is presented in a
2014 Cochrane review [34] that examined 13 studies,
two of which were randomized controlled trials (RCTs)
[11, 35]. While the included studies found some evi-
dence that e-cigarettes help smokers quit or reduce
smoking, the authors concluded that a lack of high-
quality RCTs reduces the certainty of these effects.
Nonetheless, available data from several observational
studies suggest that e-cigarettes can lead to substantial
smoking reduction among smokers not motivated to
quit [36–38]. Many smokers continue to engage in dual
use of e-cigarettes and tobacco cigarettes. A study exam-
ining the effects of cigarette reduction on cardiovascular
risk factor levels in regular smokers (15–45 cigarettes
per day) motivated to decrease their consumption demon-
strated that reducing the number of self-reported cigarettes
per day by at least 40 % led to significant improvements
(p < 0.05) in several biomarkers of cardiovascular disease
[39]. However, these were only modestly correlated with a
reduced risk of disease. Similarly modest risk reductions
found in other studies have led researchers to hypothesize
that cigarette reduction among heavy smokers is frequently
accompanied by compensatory smoking behavior, includ-
ing prolonging the duration of each cigarette smoked
[40–42]. Thus, despite improvements in biomarkers in-
cluding hemoglobin, leukocyte counts, fibrinogen, and
cholesterol, there is no evidence that reducing smoking to
as few as ten cigarettes per day produces improvements in
clinical cardiovascular disease outcomes [3].
The absence of improved cardiovascular outcomes,
however, does not preclude the existence of benefits at-
tributed to reduced smoking. A population-based cohort
study with up to 31 years of follow-up determined that
reducing smoking from 20 to fewer than ten cigarettes
per day produced a 27 % (95 % confidence interval [CI],
2–46 %) reduction in the relative risk of lung cancer as
compared to continuously smoking more than 15 ciga-
rettes per day [42]. In a second study, smokers unwilling
to quit were randomized to either 4 weeks of reduced
smoking with subsequent advice to quit or to usual care
with only quit advice [43]. Both groups had similar quit
rates at 6 months, suggesting that reduction messages
do not hinder cessation attempts. Similarly, a review of
19 controlled, cohort, case–control, and experimental
studies examining the impact of reduction messages on
smoking cessation revealed no study concluded that
smoking reduction decreases subsequent smoking cessa-
tion among smokers unwilling to quit [44]. Rather, re-
duced smoking likely constitutes a first step to attempt
and subsequently achieve abstinence, particularly among
smokers who perceive themselves as unable to quit [39].
Use of e-cigarettes among non-smokers
A key challenge faced by regulatory agencies in choosing
how to regulate e-cigarettes rests in considering the pos-
sibility of increased use among non-smokers. Data from
a 2010–2013 online survey of US adults conducted in
samples ranging from 2,505 (in 2010) to 4,170 (in 2012)
respondents revealed that ever use of e-cigarettes was
highest among current and former cigarette smokers
compared to never smokers in every survey year [45].
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Specifically, the proportion of never cigarette smokers
who reported ever use of e-cigarettes was 1.3 % in 2010,
1.3 % in 2011, 2.3 % in 2012, and 1.2 % in 2013. Similarly
in 2012, just 0.2 % of never smokers reported using an
e-cigarette in the past 30 days. The increase in e-
cigarette awareness (40.9 to 79.7 %) and ever use (3.3 to
8.5 %) among all US adults between 2010 and 2013 thus
appears to be driven by current and former smokers. At
present, it is unclear what proportion of use among
former smokers can be attributed to recent quitters’ at-
tempts to manage their cessation efforts, or to successful
quitters newly initiating e-cigarettes. However, due to
their frequent use as unapproved smoking cessation aids
[10], it is likely that many former smokers are also re-
cent quitters.
Concerns have been raised that higher rates of never
smokers initiating e-cigarettes would result in net public
health harms via increased nicotine addiction, and the
possibility for e-cigarettes to act as a gateway to tobacco
cigarettes. There is limited evidence that nicotine exerts
a priming effect on brain circuitry, which helps to ex-
plain why nicotine is frequently used as a precursor to
other hard drugs [46]. However, the implications of such
priming are unclear, particularly as concerns a possible
gateway effect of e-cigarettes to tobacco cigarettes. Te-
nets of economics dictate that risk-minimizing strategies,
including sunscreen, condoms, and travel vaccines, en-
courage more people to engage in otherwise risky activ-
ities [6]. The same should be expected of e-cigarettes,
probably leading to eventual high product uptake among
non-smokers.
A useful paradigm that reconciles liberalism and
utilitarianism in illustrating the impact of displacing a
high-risk activity with a low-risk one is the risk/use
equilibrium (Fig. 1) [47]. For instance, if e-cigarettes
reduced a smoker’s risk by 99 %, for every smoker
who switched to e-cigarettes, 100 non-smokers would
need to initiate e-cigarettes to attain no net public
health benefit. Were e-cigarettes so little as 95 % less
harmful than tobacco cigarettes, 20 % of non-smoker
uptake of e-cigarettes would be required to offset the
public health benefits of 1 % of smokers switching to
e-cigarettes, generally representing the upper limit of
nicotine usage prevalence worldwide [6]. Conse-
quently, it is unlikely that e-cigarettes would result in
net public health harms despite the inevitable uptake
of the product in a non-smoking fraction of the
population. This framework provides nuance to the
absolutist position that any non-smoker uptake of e-
cigarettes would have overall adverse effects on popu-
lation health. In practice, sound public health policy
can sustain autonomous choices with deleterious con-
sequences to the extent that these do not outweigh
net public health benefits.
It is important to consider how the risks and benefits of
tobacco harm reduction are differentially experienced by
disadvantaged populations. It is well documented that
cigarette smoking is associated with structural, material,
and perceived socioeconomic disadvantage [48, 49]. Al-
though e-cigarettes could increase health disparities if
used differentially for harm reduction, given their compar-
able cost to tobacco cigarettes, for which smokers have
already found the income to purchase, they are unlikely to
increase disparities in practice. However, this remains an
issue that requires continued surveillance to better under-
stand practices in different socioeconomic groups.
Use of e-cigarettes among youth
Nicotine liquid (e-liquid) flavourings are widely available
in youth-friendly flavors, including strawberry, bubble
gum, and chocolate. Flavored tobacco has been shown
to have a large market share among youth aged 12 to
17 years [50], confirming the attractiveness of these
products to new and young smokers and their likely
contribution to smoking initiation. The appeal of flavor-
ings is particularly disconcerting given an increase in
United States (US) reports of accidental e-cigarette ex-
posure (including exposure to e-liquid) in children [51],
Fig. 1 The risk/use equilibrium. Each point on this curve indicates
the multiplier needed to achieve a constant level of population risk,
given specific levels of decreased danger per user. For example, if
100 individuals used a product with full danger (for example, killing
100 % of users), 10 times that number (1000 individuals) would
need to use a product that had 90 % decreased danger, to achieve
an equal health problem (100 dead in each instance). The formula is
Y = 100/100-X, where Y =multiplier and X = decrease in danger,
expressed in percentages. If danger is 0.1 %, use would have to
increase by 1000 times to produce a problem of the same
magnitude as the full risk product (not plotted on figure). For a
given risk on the curve, use that is increased by a smaller multiplier
represents a public health benefit, and use that is increased by a
larger multiplier represents a public health (population level) cost.
Figure and legend reproduced from [47] with permission from BMJ
Publishing Group Ltd.
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with many bottles of e-liquid containing several times
the lethal dose of nicotine in children [52]. Previous
studies also highlight positive youth perceptions and ex-
pectations of flavored tobacco products, namely that
they are both better-tasting and safer than non-flavored
tobacco products [53]. The combination of added flavor
to a device that is also perceived to be less harmful than
tobacco cigarettes is likely to entice youth to use e-
cigarettes. Given the unknown health effects of long-
term nicotine use [3] and inhaled propylene glycol [54],
the safety profile of even the most reliable e-cigarette is
yet unknown, and the consumption of nicotine among
youth remains undesirable. For this reason, there is
widespread consensus concerning attempts to restrict e-
cigarette sales to youth in the US [55].
The gateway hypothesis has its specific application to
youth, for whom the balance of potential benefits and
risks associated with harm reduction must also be con-
sidered. Although the association between cigarette
smoking and e-cigarette use has recently been examined
in a cross-sectional study of adolescents [56], given the
study design and its temporal ambiguity, it is difficult to
draw firm conclusions from these data [57]. As it is un-
clear whether youth who use e-cigarettes are more likely
to use tobacco cigarettes as a consequence of the e-
cigarette itself, there remains a need to evaluate the
gateway hypothesis in this population over time.
Marketing and advertising
An extension of youth protection is the question of
regulating advertisement and marketing to broad audi-
ences. Comprehensive advertising bans would likely
minimize any perceived government endorsement of e-
cigarettes. However, the inadvertent message sent to
consumers by regulating e-cigarettes as strictly as to-
bacco cigarettes may be that these products are compar-
ably, if not equally harmful. E-cigarettes are likely to be
considerably less toxic than tobacco cigarettes [31] given
the absence of tobacco combustion inherent to cigarette
smoking, which releases pulmonary carcinogens includ-
ing polycyclic aromatic hydrocarbons, N-Nitrosamines,
and various other cytotoxic compounds [58]. From both
utilitarian and liberal perspectives, misinformation
through the provision of inaccurate comparative risk is
fundamentally unethical for its failure to allow con-
sumers to make informed choices, and for effectively
conveying the message that smokers may as well con-
tinue to smoke [59].
As marketing and advertisement play an important
role in the public’s perception of e-cigarettes, govern-
ments have an ethical duty to ensure that the product’s
media portrayal is appropriately aligned with its known
degree of risk. If the public health community’s aim is to
market e-cigarettes to current smokers, it follows that
advertisements should have at least equal reach to this
target audience as tobacco cigarettes. This strategy,
termed “levelling up,” would allow e-cigarettes to be sold
and marketed similarly to conventional tobacco prod-
ucts, as well as benefiting from the possibility of lower
tax rates owed to their reduced potential for harm [60].
However, the relative absence of restrictions to date in
the US has led e-cigarette marketing to permeate most
media outlets through the likes of celebrity endorse-
ments, images associated with youth culture, and state-
ments encouraging consumers to reclaim lost freedoms
[61]. Importantly, today’s youth have never known mass
marketing of a recreational nicotine product [31]. In
2014, the World Health Organization released a state-
ment encouraging government bodies to restrict e-
cigarette promotion and sponsorship, including ensuring
that any advertisement does not target youth, non-
smokers, or people not using nicotine [62]. However, be-
cause e-cigarettes are not currently regulated as tobacco
products in the US, they are neither subject to clear nor
comprehensive regulations.
Use of e-cigarettes in public places
Ethical concerns surrounding second-hand vaping stem
from the unknown health effects of vaporized e-liquid in
the presence of potentially vulnerable bystanders. Al-
though e-cigarettes emit significantly fewer toxins than
tobacco cigarettes [63], vaporized e-liquid produces ul-
trafine particles and volatile organic compounds, includ-
ing nicotine, which are released into the surrounding air
[64]. One study concluded that aerosolized ingredients
contained in e-liquid should be of little concern to by-
standers as their exposure is likely orders of magnitude
lower than that of e-cigarette users and is unlikely to
produce adverse health effects [54]. However, studies
examining the cytotoxicity of e-liquid flavorings found
toxicity to be greater in undifferentiated embryonic stem
cells relative to human pulmonary fibroblasts [65], rais-
ing potential concerns about exposure risks for pregnant
women [31]. Beyond any immediate emission concerns
however, the ethical arguments surrounding second-
hand vapor exposure are those that apply to tobacco cig-
arettes: exposure to e-cigarettes should not be imposed
upon those who do not choose to use them, providing a
strong argument for use restrictions in public places.
Renormalization of a smoking culture
E-cigarettes theoretically have the potential to subvert
decades’ worth of anti-smoking efforts by renormaliz-
ing the act of public smoking and the visual presence
of smoke-like vapor. This phenomenon could unin-
tentionally encourage the acceptability and eventual
uptake of tobacco cigarettes. However, the likelihood
of such a phenomenon is difficult to assess and is
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premised upon e-cigarettes’ potential to act as a gate-
way to cigarette smoking. One possibility is that the
increased conspicuousness of smoke-like vapor may
sustain cigarette smoking among smokers who might
otherwise have quit [66]. Conversely, the growing ac-
ceptability of e-cigarettes could increase pressure on
current smokers to quit tobacco cigarettes by virtue
of these becoming perceived as socially undesirable
predecessors of a “cleaner,” smoke-free device. This
question should be continuously revisited as the long-
term implications of e-cigarette use become increas-
ingly clear.
Market ownership
As cigarette companies have acquired the largest e-
cigarette brands, they currently benefit from a dual
Table 1 Ethical considerations surrounding the availability and use of e-cigarettes




E-cigarettes may be as effective as
the nicotine patch.
Inconclusive evidence of efficacy for
smoking cessation.
What is the efficacy of nicotine and non-




Demonstrated in multiple studies. Unlikely that cigarette reduction
results in significant health benefits.
What is the long-term impact of dual use of





Unknown impact of long-term pro-
pylene glycol inhalation.
No documented serious adverse
events to date.
What are the long-term safety implications
of nicotine and non-nicotine e-cigarette use?
Propylene glycol inhalation causes
short-term respiratory irritation.
Autonomy to use a
product of unknown
risk
Ethical imperative given informed
consent.
Public health concerns trump
individual rights.
How should consumer rights be weighed
against public health concerns?
Use among non-smokers
Potential to lead to
nicotine addiction
Perceived harmlessness may lead
never smokers to initiate e-
cigarettes.
No evidence for increased nicotine
addiction to cause net public health
harms.




Nicotine acts as a priming agent for
the brain.
Unclear implications for transitioning
to tobacco cigarettes.
How many non-smokers initiating e-
cigarettes transition to other tobacco prod-
ucts, including cigarettes?
Use among youth
Potential to lead to
nicotine addiction
Minors require protection. No evidence of increased nicotine
addiction causing net public health
harms.
How many youth initiating e-cigarettes re-
port continuous long-term product use




Nicotine is a priming agent for the
brain.
Unclear implications for transitioning
to tobacco cigarettes.
How many youth initiating e-cigarettes tran-




Increased calls to poison control
centers.
None. To what extent can the risk of nicotine
poisoning among children be mitigated?
E-liquid flavors are appealing to
youth.
Use in public places
Potential for passive
vaping
Stem cell cytotoxicity. Limited evidence that passive vaping
poses significant health concerns.
What is the long-term impact of passive vap-






Increased acceptability of smoke-like
vapor and smoking behavior.
No evidence that e-cigarettes would
be conflated with tobacco cigarettes.
How are the increased awareness and use of






Public health endorsement of e-
cigarettes increases tobacco com-
pany market share.
Possible necessity to collaborate with
the tobacco industry to achieve public
health gains.
What are the public health implications of
tobacco industry ownership of major e-
cigarette brands?
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market of smokers and e-cigarette users while simultan-
eously presenting themselves as agents of harm reduction
[31, 67]. This raises concerns about the appropriateness of
endorsing a product that directly profits the tobacco in-
dustry. Importantly, profit alone is unlikely to increase
their market share, particularly in the highly restrictive
regulatory environment in which tobacco companies op-
erate. In addition, the unequivocal refusal to associate with
the tobacco industry which appears, if only for self-serving
reasons, to support tobacco harm reduction [68], could
unintentionally damage the credibility of the tobacco con-
trol community. Regardless of their industry ownership, e-
cigarette companies would nevertheless have a vested
interest in maximizing the number of long-term product
users. The ethical onus then falls on governments to re-
strict the influence of industry through appropriate regula-
tions targeting product manufacturing, availability, and
use, devised in light of public health interests.
Directions for future research
There is an urgent need for data from high-quality RCTs
to establish the efficacy and safety of e-cigarettes for
smoking cessation and harm reduction. In addition, lon-
gitudinal studies are needed to monitor product aware-
ness and use among various demographics and to
further inform discussions concerning the potential of e-
cigarettes as tools for tobacco harm reduction. We iden-
tified the primary research questions relevant to the
ethical considerations of e-cigarette use for tobacco
harm reduction (Table 1), the answers to which would
clarify the major ambiguities concerning their optimal
regulatory framework. Until such study data become
available, governments have an ethical responsibility to
enforce regulations to discourage product use among
youth and to ensure that product restrictions are devised
with public health goals in mind. Available evidence
therefore supports the cautionary implementation of
harm reduction interventions aimed at promoting e-
cigarettes as attractive and competitive alternatives to
cigarette smoking, while taking measures to protect vul-
nerable groups and individuals.
Conclusions
In light of incomplete information concerning the safety
and efficacy of e-cigarettes as smoking cessation aids,
thresholds of reasonable risk must be established
through a frequently revisited balance of probable bene-
fits and harms with which they are associated. Their ex-
ponential growth in consumer markets has outpaced the
development of an ethical framework with which to es-
tablish the appropriate conditions for their availability
and use. Current evidence suggests that e-cigarettes have
the potential to make significant public health gains
through their role as tobacco harm reduction devices. In
clinical practice, physicians have an ethical duty to pro-
vide their patients with evidence-based comparative risk
assessments to allow them to make informed choices
with respect to their smoking status. At its core, the ob-
jective of the smoking cessation agenda should be to im-
prove population health, which will likely require some
concessions in the form of harm reduction. This entails
a willingness to negotiate the tensions between utilitar-
ian and liberal ethics in designing policy that upholds
autonomy while protecting broader public health inter-
ests. Although caution in this regard is requisite, caution
alone should not obstruct the ethical imperative to ex-
plore the product’s potential further.
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